[1] |
Francque S, Szabo G, Abdelmalek MF, et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(1): 24-39.
doi: 10.1038/s41575-020-00366-5
pmid: 33093663
|
[2] |
Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial[J]. Lancet, 2018, 391(10120): 541-551.
doi: S0140-6736(17)33102-1
pmid: 29221645
|
[3] |
Baek SJ, Okazaki R, Lee SH, et al. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia[J]. Gastroenterology, 2006, 131(5): 1553-1560.
doi: 10.1053/j.gastro.2006.09.015
pmid: 17101328
|
[4] |
Xiong Y, Walker K, Min X, et al. Long-acting MIC-1/GDF15 molecules to treat obesity: evidence from mice to monkeys[J]. Sci Transl Med, 2017, 9(412).
|
[5] |
Baek SJ, Eling T. Growth differentiation factor 15 (GDF15)[J]. Pharmacol Ther, 2019, 198: 46-58.
doi: 10.1016/j.pharmthera.2019.02.008
URL
|
[6] |
Hsu JY, Crawley S, Chen M, et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15[J]. Nature, 2017, 550(7675): 255-259.
doi: 10.1038/nature24042
URL
|
[7] |
Tsai VWW, Husaini Y, Sainsbury A, et al. The MIC-1/GDF15-GFRAL pathway in energy homeostasis[J]. Cell Metab, 2018, 28(3): 353-368.
doi: 10.1016/j.cmet.2018.07.018
URL
|
[8] |
Wiklund FE, Bennet AM, Magnusson PK, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15)[J]. Aging Cell, 2010, 9(6): 1057-1064.
doi: 10.1111/j.1474-9726.2010.00629.x
URL
|
[9] |
Ahmed DS, Isnard S, Lin J, et al. GDF15/GFRAL pathway as a metabolic signature for cachexia in patients with cancer[J]. J Cancer, 2021, 12(4): 1125-1132.
doi: 10.7150/jca.50376
pmid: 33442410
|
[10] |
Yang L, Chang CC, Sun Z, et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand[J]. Nat Med, 2017, 23(10): 1158-1166.
doi: 10.1038/nm.4394
pmid: 28846099
|
[11] |
Mullican SE, Lin-Schmidt X, Chin CN, et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates[J]. Nat Med, 2017, 23(10): 1150-1157.
doi: 10.1038/nm.4392
pmid: 28846097
|
[12] |
Emmerson PJ, Wang F, Du Y, et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL[J]. Nat Med, 2017, 23(10): 1215-1219.
doi: 10.1038/nm.4393
pmid: 28846098
|
[13] |
Tsai VW, Macia L, Johnen H, et al. TGF-b superfamily cytokine MIC-1/GDF15 is a physiological appetite and body weight regulator[J]. PLoS One, 2013, 8(2): e55174.
doi: 10.1371/journal.pone.0055174
URL
|
[14] |
Chung HK, Ryu D, Kim KS, et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis[J]. J Cell Biol, 2017, 216(1): 149-165.
doi: 10.1083/jcb.201607110
pmid: 27986797
|
[15] |
Chrysovergis K, Wang X, Kosak J, et al. NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism[J]. Int J Obes(Lond), 2014, 38(12): 1555-1564.
doi: 10.1038/ijo.2014.27
|
[16] |
Frikke-Schmidt H, Hultman K, Galaske JW, et al. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice[J]. Mol Metab, 2019, 21: 13-21.
doi: S2212-8778(18)31143-8
pmid: 30685336
|
[17] |
Dolo PR, Yao L, Liu PP, et al. Effect of sleeve gastrectomy on plasma growth differentiation factor-15 (GDF15) in human[J]. Am J Surg, 2020, 220(3):725-730.
doi: S0002-9610(20)30053-2
pmid: 32014297
|
[18] |
Kleinert M, Bojsen-Møller KN, Jørgensen NB, et al. Effect of bariatric surgery on plasma GDF15 in humans[J]. Am J Physiol Endocrinol Metab, 2019, 316(4): E615-E621.
doi: 10.1152/ajpendo.00010.2019
URL
|
[19] |
Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin[J]. Diabetologia, 2017, 60(9): 1577-1585.
doi: 10.1007/s00125-017-4342-z
pmid: 28776086
|
[20] |
Gerstein HC, Pare G, Hess S, et al. Growth differentiation factor 15 as a novel biomarker for metformin[J]. Diabetes Care, 2017, 40(2): 280-283.
doi: 10.2337/dc16-1682
pmid: 27974345
|
[21] |
Coll AP, Chen M, Taskar P, et al. GDF15 mediates the effects of metformin on body weight and energy balance[J]. Nature, 2020, 578(7795): 444-448.
doi: 10.1038/s41586-019-1911-y
|
[22] |
Zhao J, Li M, Chen Y, et al. Elevated serum growth differentiation factor 15 levels in hyperthyroid patients[J]. Front Endocrinol (Lausanne), 2019, 9: 793.
doi: 10.3389/fendo.2018.00793
URL
|
[23] |
Breit SN, Brown DA, Tsai VW. The GDF15-GFRAL pathway in health and metabolic disease[J]. Annu Rev Physiol, 2021, 83: 127-151.
doi: 10.1146/physiol.2021.83.issue-1
URL
|
[24] |
Tsai VW, Zhang HP, Manandhar R, et al. GDF15 mediates adiposity resistance through actions on GFRAL neurons in the hindbrain AP/NTS[J]. Int J Obes (Lond), 2019, 43(12): 2370-2380.
doi: 10.1038/s41366-019-0365-5
|
[25] |
Johnen H, Lin S, Kuffner T, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1[J]. Nat Med, 2007, 13(11): 1333-1340.
doi: 10.1038/nm1677
pmid: 17982462
|
[26] |
Hale C, Véniant MM. Growth differentiation factor 15 as a potential therapeutic for treating obesity[J]. Mol Metab, 2021, 46: 101117.
doi: 10.1016/j.molmet.2020.101117
URL
|
[27] |
Patel S, Alvarez-Guaita A, Melvin A, et al. GDF15 provides an endocrine signal of nutritional stress in mice and humans[J]. Cell Metab, 2019, 29(3): 707-718.
doi: S1550-4131(18)30753-8
pmid: 30639358
|
[28] |
Campderrós L, Moure R, Cairó M, et al. Brown adipocytes secrete GDF15 in response to thermogenic activation[J]. Obesity, 2019, 27(10): 1606-1616.
doi: 10.1002/oby.22584
pmid: 31411815
|
[29] |
Lee SE, Kang SG, Choi MJ, et al. Growth differentiation factor 15 mediates systemic glucose regulatory action of T-helper type 2 cytokines[J]. Diabetes, 2017, 66(11): 2774-2788.
doi: 10.2337/db17-0333
pmid: 28874416
|
[30] |
Eddy AC, Trask AJ. Growth differentiation factor-15 and its role in diabetes and cardiovascular disease[J]. Cytokine Growth Factor Rev, 2021, 57: 11-18.
doi: 10.1016/j.cytogfr.2020.11.002
URL
|